SK Pharmteco announced it will invest over $200 million over the next five years to expand and advance its development and production infrastructure in the United States.
Key points
•SK Pharmteco to invest over $200 million in U.S. to expand small molecule drug and peptide production capacity
•Plans include building state-of-the-art development research centers and advanced peptide purification facilities
•Expected to create over 100 high-skilled jobs in the U.S. in the long term
SK Pharmteco announced plans to invest over $200 million to strengthen its infrastructure for small molecule drugs and peptides in the U.S., responding to the demand from a wide range of customers. This investment is part of the company's global growth strategy and is expected to create over 100 high-skilled jobs in the U.S. in the long term.
The investment plan includes establishing state-of-the-art development research centers and advanced peptide purification facilities. Additionally, the company plans to build new production facilities, modernize existing GMP production capabilities, and improve utility facilities for sustainable operations.
Jorg Algren, CEO of SK Pharmteco, emphasized that this investment will be a major turning point for the company, stating that the company is committed to providing high reliability and sustainability to its customers.
